Targeted inhibition of the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis by combining JQ1 and an anti-PD-1 antibody or an immune-stimulating anti-4-1BB antibody in mouse models with Myc-driven lymphomas showed that treatment with anti-PD1, JQ1, or anti-4-1BB alone was partially effective; however, the co-treatment resulted in more robust and sustained outcomes [91]. Here, TNFRSF9 is linked to lymphoma.